drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular immunotherapy)
drug_description
Autologous, gene-modified T cells engineered to express a CAR targeting CD19 on malignant B cells, inducing T-cell activation and cytotoxic killing of tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD19 on B cells; upon antigen engagement, CAR signaling (CD3ζ with costimulatory domains such as CD28 or 4‑1BB) activates the T cells to proliferate, secrete cytokines, and mediate cytotoxic killing of CD19‑positive malignant B cells.
drug_name
CD19-directed chimeric antigen receptor (CAR) T cells
nct_id_drug_ref
NCT05800405